(Q71403909)
Statements
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group (English)
B Pignon
F Witz
B Desablens
P Y Leprise
S Francois
C Linassier
C Berthou
D Caillot
B Lioure
J Y Cahn
P Casassus
A Sadoun
B Audhuy
D Guyotat
J Briere
J P Vilque
L Baranger
V Polin
P Berthaud
P Hurteloup
P Herve